Status:
UNKNOWN
Atherosclerosis in Atrial Fibrillation
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Atrial Fibrillation
Metabolic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The prevalence of metabolic syndrome in patients suffering from non valvular atrial fibrillation is derived from studies regarding recurrences of atrial fibrillation after catheter ablation. Prospecti...
Detailed Description
Atrial fibrillation (AF) is the most common cardiac arrhythmia that is associated with a high risk of cardiovascular events and increased morbidity and mortality. Cardiovascular events are prevalently...
Eligibility Criteria
Inclusion
- non valvular atrial fibrillation
- age \>18 years
- any antithrombotic treatment
Exclusion
- prosthetic heart valves, or the presence of any severe valvulopathies, severe cognitive impairment, chronic infectious (HIV, hepatitis C, HBV) or autoimmune systemic disease. Furthermore, subjects were excluded from the study if they had active neoplastic diseases or liver insufficiency (eg, cirrhosis).
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT01882114
Start Date
November 1 2007
End Date
December 1 2020
Last Update
February 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Umberto I Policlinico di Roma, Sapienza Università di Roma
Rome, Italy, 00155